Double-Drug attack on Hard-to-Treat prostate cancer begins human testing
NCT ID NCT07082920
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a combination of two experimental drugs—Pasritamig and ARX517—in 140 men with metastatic castration-resistant prostate cancer, a form that has spread and no longer responds to hormone therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pasritamig (JNJ-78278343) and ARX517 (JNJ-95298177)
What this could lead to
If successful, this could lead to a new combination treatment option for advanced prostate cancer that has stopped responding to hormone therapy.
What could go wrong
This is an early phase 1 trial, so safety and dosing are still being figured out. The drugs may cause serious side effects like cytokine release syndrome, and there is no guarantee they will shrink tumors or extend life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University Medical Center
RECRUITINGNew York, New York, 10032, United States
-
Florida Cancer Specialists
RECRUITINGSarasota, Florida, 34232, United States
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
-
Royal Marsden Hospital (Sutton)
RECRUITINGSutton, SM2 5PT, United Kingdom
-
The Christie Nhs Foundation Trust
RECRUITINGManchester, M20 4BX, United Kingdom
-
University Hospitals Cleveland Medical Center
RECRUITINGCleveland, Ohio, 44106, United States